# Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF

**Authors:** Shirley Y. Jiang, Shu Cao, Kristine Martinez, Reyna Sharma, Olivia Raeber, Andrea Fernandes, Dinara Bogetic, Abhinav Kaushik, Sheena Gupta, Monali Manohar, Holden T. Maeker, Andrew R. Chin, Andrew J. Long, Catherine Feight, Margaret Woch, Kari C. Nadeau, R. Sharon Chinthrajah, Sayantani B. Sindher

PMC · DOI: 10.3389/falgy.2025.1458131 · Frontiers in Allergy · 2025-07-22

## TL;DR

A clinical trial tested shrimp oral immunotherapy and found it safe and effective for treating shrimp allergy in most participants.

## Contribution

The study provides evidence that shrimp oral immunotherapy can induce desensitization and sustained unresponsiveness in shrimp-allergic individuals.

## Key findings

- 58.3% of participants achieved desensitization to shrimp after 52 weeks of oral immunotherapy.
- 87.5% of participants who completed the study achieved sustained unresponsiveness after 6 weeks of avoidance.
- Adverse events were mostly mild, with no severe reactions or epinephrine use reported.

## Abstract

Shrimp is a common but understudied food allergen with relatively high rates of emergency department visits. Here we report the shrimp OIT outcomes in the MOTIF (NCT03504774) clinical trial and discuss some of the challenges with performing this study.

In this phase 2 clinical trial, 12 shrimp allergic participants aged 7–55 years (median age 21.5 years) were enrolled to receive shrimp OIT. Shrimp OIT was performed up to a maintenance dose of 1,000 mg shrimp protein by week 28 with desensitization to shrimp assessed by double-blind placebo-controlled food challenge at week 52 followed by switching to avoidance and assessing sustained unresponsiveness (SU) at week 58. The primary endpoint was the change in CD28 in CD4+ allergen specific (CD154+) T-cells at baseline and 52 weeks.

Shrimp OIT induced desensitization to a cumulative 4,043 mg shrimp protein in 58.3% (7/12) of the intention to treat and 87.5% (7/8) of the per protocol group after 52 weeks of shrimp OIT. Most shrimp OIT participants who remained in the study after desensitization (87.5%, 7/8) achieved SU. Although adverse events were common during shrimp OIT (75%), most were mild (Bock grade 1, 88%) and there were no severe (Bock grade 3+) reactions or use of epinephrine. No significant differences in CD28 expression were observed after shrimp OIT.

Shrimp OIT is safe and effective for the treatment of shrimp allergy. Most participants were successful and achieved SU after 6 weeks of avoidance.

## Linked entities

- **Proteins:** CD28 (CD28 molecule), CD4 (CD4 molecule), CD40LG (CD40 ligand)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}
- **Diseases:** allergic (MESH:D004342)
- **Chemicals:** Shrimp (-), epinephrine (MESH:D004837)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12321884/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12321884/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12321884/full.md

---
Source: https://tomesphere.com/paper/PMC12321884